Brittany Eirich, MD
Internal Medicine · Scottsbluff, NENPI 1225393390
Payments from drug & device makers
Across 16 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$87
- Verona Pharma, Inc.$36
- Mylan Specialty L.p.$31
- E.r. Squibb & Sons, L.L.C.$30
- Takeda Pharmaceuticals U.S.A., Inc.$18
- Merck$17
- plus $73 from 5 others
What the payments were for
- Food & beverage$293100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| Verona Pharma, Inc. | 1 | $36 |
| Mylan Specialty L.p. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$293 in reported general payments places this provider in the 65th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $164,029 |
| OzempicSemaglutide | 87 | $106,301 |
| MounjaroTirzepatide | 46 | $60,007 |
| JardianceEmpagliflozin | 60 | $49,643 |
| TrulicityDulaglutide | 34 | $47,486 |
| XareltoRivaroxaban | 52 | $45,839 |
| Xtampza ErOxycodone Myristate | 13 | $28,570 |
| MyrbetriqMirabegron | 36 | $18,120 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 64 | $14,191 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $12,457 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $8,714 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $8,312 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $8,139 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $7,927 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,764 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Scottsbluff
- Mohammed SalhabScottsbluff$9K
- Scott RasmussenLincoln$38.1M
- Charles HarperNorfolk$31.1M
- Robert SchwabBoys Town$9.2M
- Michael DunnOmaha$7.9M
- Alexander RyanLincoln$2.2M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Timothy HuyckPapillion$702K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.